Oncology Central

Nivolumab, ipilimumab combination succeeds in Phase III lung cancer trial

Findings from an ongoing Phase III study investigating first-line non-small cell lung cancer (NSCLC) patients who have a high tumor mutation burden (TMB) have been announced by Bristol-Myers Squibb (NY, USA), demonstrating promising progression-free survival rates.

The CheckMate-227 study enrolled over 2500 non-small cell lung cancer (NSCLC) patients, randomized across squamous and non-squamous histologies, treated with a combination of Opdivo® (nivolumab) and Yervoy® (ipilimumab) versus standard chemotherapy.

The patients also expressed high TMB, regardless of PD-L1 expression. TMB is classified as ten or more mutations per megabase, a measure which is emerging as a useful oncologic biomarker.

Bristol-Myers Squibb stated that the current findings are based on Part 1 of the trial’s investigation, comprising Part 1a, examining Opdivo and Yervoy and monotherapy versus chemotherapy in patients whose tumors express PD-L1, and

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.